BN
|
HealthAI Desk•4 views

Eli Lilly's Retatrutide Succeeds in First Phase 3 Diabetes Trial, Shows Significant Weight Loss

Eli Lilly's retatrutide achieved its primary endpoints in a phase 3 Type 2 diabetes trial, reducing blood sugar by 1.7-2% and weight by up to 16.8% over 40 weeks. The drug, which targets three hunger hormones, primarily caused gastrointestinal side effects with low discontinuation rates. Compared to Lilly's Zepbound, retatrutide offered greater weight loss but similar blood sugar improvements. Novo Nordisk is pursuing a competing therapy but is less advanced. Lilly plans to release more trial data soon and has not yet sought drug approval.

Ad slot
Eli Lilly's Retatrutide Succeeds in First Phase 3 Diabetes Trial, Shows Significant Weight Loss

Eli Lilly announced that its experimental obesity drug retatrutide successfully met its primary goals in the first phase 3 trial for Type 2 diabetes patients, demonstrating substantial reductions in blood sugar levels and body weight.

Trial Efficacy Results

  • Retatrutide lowered hemoglobin A1c by an average of 1.7% to 2% across different doses at 40 weeks compared to placebo, meeting the main study goal.
  • Patients started with A1c levels between 7% and 9.5% and were not using other diabetes medications.
  • At the highest dose, weight loss averaged 16.8% (36.6 pounds) over 40 weeks among completers; including all participants, loss was 15.3%.

Safety and Side Effects

  • Primary adverse events were gastrointestinal: nausea (26.5% at high dose), diarrhea (22.8%), and vomiting (17.6%).
  • Discontinuation rates due to side effects were up to 5%, described as relatively low by Lilly.
  • Low incidence of dysesthesia (unpleasant nerve sensations) was reported.

Drug Mechanism and Comparisons

  • Retatrutide, known as "triple G," mimics three hormones—GLP-1, GIP, and glucagon—unlike existing treatments that target one or two.
  • Compared to Lilly's Zepbound (tirzepatide), retatrutide showed greater weight loss but similar A1c reduction:
    • Zepbound in SURPASS-2: 13.1% weight loss at high dose.
    • Zepbound in SURPASS-1: 11% weight loss at high dose.
  • No direct head-to-head trials exist, limiting precise efficacy comparisons.

Competitive Landscape and Future Steps

  • Novo Nordisk is developing a similar three-hormone drug but is in earlier stages after a 2025 acquisition.
  • Lilly expects results from seven additional phase 3 trials by year-end but has not yet filed for regulatory approval for obesity or diabetes.
  • Ken Custer, president of Lilly Cardiometabolic Health, highlighted the need for personalized treatment options, noting retatrutide's A1c reduction is "very, very strong" versus non-gut-hormone diabetes drugs.
Ad slot
Ad slot